Latest Evolution in Antiviral Drug Resistance
The viral infectious disease is anticipated to remain a major public health problem in the coming decades, which poses a threat to both national and international health security. Endemic diseases including, human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) will continue to challenge public health. For the early detection and rapid response, high level of awareness is required across the region. Thus, the rapid growth and innovations coming from the emerging nations are expected to increasing the growth opportunities and sales in the global antiviral drug resistance market.
Viruses are the tinier germs that can cause several infectious diseases such as flu, common cold, and warts. Viruses can also cause severe illnesses, including smallpox, HIV/AIDS, and Ebola. Viruses reproduce inside cells and able to enter into any living, healthy cells and multiply and produce other viruses like themselves. Different viruses attack specific cells in the body such as liver, brain, skin, blood and also reproductive, respiratory, and gastrointestinal systems.
The prevalence of virus infections such as hepatitis has increased during recent years across the globe. Hepatitis causes liver damage and inflammation that can also damage other organs. It is a major global health problem that can cause chronic infection and also upsurge the higher risk of death from cirrhosis and liver cancer.
The increasing healthcare expenditure in the emerging economies such as Asia Pacific and South and Central America are enabling the researchers to develop treatment options for a wide range of viral diseases by utilizing advanced techniques such as PCR (Polymerase Chain Reaction), next generation sequencing and others.
Leading Players Involved in this Study:
- Danaher
- Abbott
- BD
- F. Hoffmann-La Roche Ltd
- Trinity Biotech
- Seimens AG
- bioMĂ©rieux SA
- Bio-Rad Laboratories, Inc
- AccuBioTech Co., Ltd.
- ACON Laboratories, Inc.